You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana
|
|---|---|
| Published in |
Journal of Pharmaceutical Policy and Practice, April 2017
|
| DOI | 10.1186/s40545-017-0103-0 |
| Pubmed ID | |
| Authors |
Alexander Freeman, Anthony Kwarteng, Lawrence Gyabaa Febir, Seeba Amenga-Etego, Seth Owusu-Agyei, Kwaku Poku Asante |
| Abstract |
The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in 8 malaria endemic countries in Africa. The WHO supervised the manufacture of the subsidized products, named them Quality Assured ACTs (QAACT) and printed a Green Leaf Logo on all QAACT packages. Ghana began to receive the subsidized QAACTs in 2010. A cross-sectional stock survey was conducted at 63 licensed chemical shops (LCS) and private pharmacies in two districts of the Brong-Ahafo region of Ghana to determine the availability and price of all anti-malarial treatments. Drug outlets were visited over a 3-weeks period in October and November of 2014, about 2 years after the end of AMFm program. At least one QAACT was available in 88.9% (95% CI 80.9% - 96.8%) of all drug outlets with no difference between urban and rural locations. Non-Assured ACTs (NAACT) were significantly more available in urban drug outlets [75.0% availability (95% CI 59.1% - 90.9%)] than in rural drug outlets [16.1% availability (95% CI 2.4% - 29.9%)]. The top selling product was Artemether Lumefantrine with the Green Leaf Logo, a QAACT. There was a significant difference in the mean price of a QAACT [$1.04 USD (95% CI $0.98 - $1.11)], and the mean price of a NAACT in both the urban and rural areas [$2.46 USD (95% CI $2.11 - $2.81)]. There was no significant difference in the price of any product that was available in urban and rural settings. About 2 years after the AMFm program, subsidized QAACTs in Ghana were widely available and more affordable than NAACTs in the Kintampo North District and Kintampo South Municipality of Ghana. The AMFm program appeared to have mostly succeeded in making QAACTs available and affordable. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 50% |
| Switzerland | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Science communicators (journalists, bloggers, editors) | 2 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 17% |
| Student > Bachelor | 4 | 11% |
| Researcher | 4 | 11% |
| Student > Doctoral Student | 3 | 9% |
| Student > Ph. D. Student | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 12 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 23% |
| Medicine and Dentistry | 5 | 14% |
| Nursing and Health Professions | 3 | 9% |
| Economics, Econometrics and Finance | 2 | 6% |
| Unspecified | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 13 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2017.
All research outputs
#7,016,483
of 22,968,808 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#169
of 411 outputs
Outputs of similar age
#110,893
of 310,521 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#4
of 6 outputs
Altmetric has tracked 22,968,808 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 411 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,521 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.